Sarilumab Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 150 mg/1.14 mL, 200 mg/1.14 mL

Reference Brands: Kevzara (USA/EU)

Category: Immune Disorder

Sarilumab is a fully human monoclonal antibody that targets the interleukin‑6 (IL‑6) receptor (both membrane‑bound and soluble forms). By blocking IL‑6 from binding to its receptor, sarilumab inhibits the IL-6 mediated inflammatory signaling pathway. This reduces inflammation, immune‑mediated damage, and other symptoms associated with autoimmune inflammatory diseases such as rheumatoid arthritis and polymyalgia rheumatica.

Product Description:

Sarilumab is a fully human monoclonal antibody that binds both the soluble and membrane-bound forms of the interleukin-6 receptor, blocking IL-6 signalling. IL-6 drives the systemic features of inflammatory disease — the acute phase response, anaemia of chronic disease, fatigue — as well as joint destruction, which is why blocking it produces a clinical picture different from TNF inhibition.

It is used for moderate to severe rheumatoid arthritis in adults who have responded inadequately to other disease-modifying drugs, and for polymyalgia rheumatica in patients who cannot taper off corticosteroids — an indication that matters because PMR is common in older people and long-term steroid use causes fractures, diabetes and infection. It is given by subcutaneous injection every two weeks. Blocking IL-6 suppresses the acute phase response, so CRP and fever can be absent during a serious infection, which delays recognition. Neutropenia, raised transaminases and raised lipids require monitoring, and gastrointestinal perforation is a recognised risk in patients with diverticulitis.

Sourcing notes. Originator biologic, on patent, no biosimilar. Cold chain, with a defined room-temperature period. Prefilled syringe and pen are separate presentations. It competes directly with tocilizumab, which now has biosimilars — a significant pricing pressure.